EAN
IOVA icon

Excelsior Advisor Network’s Iovance Biotherapeutics IOVA Stock Holding History

Excelsior Advisor Network’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.42M Buy
1,783,924
+1,769,774
+12,507% +$6.72M 0.98% 23
2026
Q1 		$49.7K Sell
14,150
-1,000
-7% -$3.2K 0.02% 226
2025
Q4 		$41.4K Buy
+15,150
New +$35K 0.02% 168

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Excelsior Advisor Network's IOVA Position: Q2 2026 in Review

Excelsior Advisor Network increased its Iovance Biotherapeutics (IOVA) stake by 12,507% in Q2 2026, buying an estimated $6.72M and bringing the position to 1,783,924 shares worth $7.42M. The position accounts for 0.98% of the portfolio, ranked #23.

Excelsior Advisor Network first reported a position in IOVA in Q4 2025 and has held it in 3 quarters since. 291 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Excelsior Advisor Network held 1,783,924 shares of Iovance Biotherapeutics worth $7.42M as of Q2 2026.
  • Excelsior Advisor Network bought 1,769,774 Iovance Biotherapeutics shares in Q2 2026, an estimated $6.72M.
  • Iovance Biotherapeutics made up 0.98% of Excelsior Advisor Network's portfolio in Q2 2026, its #23 holding.
  • Excelsior Advisor Network first reported a position in Iovance Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 291 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Excelsior Advisor Network's 13F filing for Q2 2026, filed 14 Aug 2026.